Topiramate injection - CyDex

Drug Profile

Topiramate injection - CyDex

Alternative Names: Captisol®-enabled topiramate IV; Captisol®-enabled topiramate injection

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer CyDex Pharmaceuticals; University of Minnesota
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures; Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy; Seizures

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 14 Aug 2013 Captisol®-enabled topiramate injection licensed to CURx Pharmaceuticals worldwide
  • 26 Jul 2013 Phase-I clinical trials in Epilepsy in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top